Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$10.71 - $17.11 $918,918 - $1.47 Million
-85,800 Reduced 31.25%
188,800 $2.38 Million
Q2 2024

Aug 14, 2024

BUY
$3.89 - $20.97 $432,568 - $2.33 Million
111,200 Added 68.05%
274,600 $3.48 Million
Q1 2024

May 15, 2024

SELL
$3.76 - $6.02 $573,400 - $918,049
-152,500 Reduced 48.27%
163,400 $781,000
Q4 2023

Feb 14, 2024

SELL
$4.8 - $7.67 $1.02 Million - $1.62 Million
-211,600 Reduced 40.11%
315,900 $1.52 Million
Q3 2023

Nov 15, 2023

BUY
$6.81 - $9.74 $3.59 Million - $5.14 Million
527,500 New
527,500 $3.82 Million

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $680M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.